A carregar...
Real-World Outcomes of Ivacaftor Treatment in People with Cystic Fibrosis: A Systematic Review
Cystic fibrosis (CF) is a rare, progressive, multi-organ genetic disease. Ivacaftor, a small-molecule CF transmembrane conductance regulator modulator, was the first medication to treat the underlying cause of CF. Since its approval, real-world clinical experience on the use of ivacaftor has been do...
Na minha lista:
| Publicado no: | J Clin Med |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8038673/ https://ncbi.nlm.nih.gov/pubmed/33917386 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm10071527 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|